Email
Print
Cryptococcosis Market Overview
Cryptococcosis Market Size is estimated to reach $6620 Million by 2030 and is poised to grow at a CAGR of 4.70%% over the forecast period of 2024-2030.
Cryptococcosis is an infection commonly associated with immunosuppressive individuals and is caused by Cryptococcus fungus. The initial symptoms are frequently chronic and develop over more than a few weeks. Meningitis (brain infection) and pulmonary infection or lung infection are the two main physical symptoms of the illness. Numerous factors, including an increase in AIDS prevalence and prolonged use of immunosuppressive medications, have contributed to an increase in the incidence of cryptococcosis over time. Patients who are HIV+ are more likely to contract a fungus. Every year, there are about 220,000 occurrences of cryptococcal meningitis among HIV/AIDS patients globally, leading to almost 181,000 deaths. For the diagnosis of the infections, the use of cryptococcal antigen, chest x-ray, lumber puncture, urine test and other diagnostics methods are used. According to HIV.gov, there were approximately 38.4 million people across the globe with HIV in 2020. Of these, 36.7 million were adults and 1.7 million were children (<15 years old). In addition, 54% were women and girls. Such growing prevalence of HIV & AIDS and the high risk of Cryptococcosis infection in this population fuel demand for better therapeutics and treatment which propel the growth of the Cryptococcosis industry over the forecast period 2024-2030.
Cryptococcosis Market Report Coverage
The report: “Cryptococcosis Market Forecast (2024-2030)" by Industry ARC, covers an in-depth analysis of the following segments in the Cryptococcosis Market.
Key Takeaways
- Geographically, North America held a dominant market share in the year 2021. Better diagnostic techniques in this region and various treatments available to cure such infections boost the growth of the Cryptococcosis Market size.
- The Cryptococcosis Market is predicted to increase due to the increase in consumption of immunosuppressant drugs and the growing prevalence of autoimmune diseases, fuelling the growth of the Cryptococcosis Market.
- However, the unavailability of proper diagnostic techniques may limit the cryptococcosis industry growth over the forecast period 2024-2030.
- A detailed analysis of strengths, weaknesses, opportunities and threats would be provided in the Cryptococcosis Market Report.
Cryptococcosis Market: Market Share (%) by region, 2021
For More Details On this report - Request For Sample
Cryptococcosis Market Segment Analysis - by Treatment
The Cryptococcosis Market based on the treatment can be further segmented into Amphotericin B (Amphocin and Fungizone), Flucytosine (Ancobon), Fluconazole Drugs (Diflucan), Voriconazole and Surgery Treatment. The Amphotericin B (Amphocin and Fungizone) segment held a dominant market share in the year 2021. As Amphotericin B is useful in the first treatment for widespread cryptococcosis infection. According to the research article published in the New England Journal of Medicine in March 2022, the World Health Organization–recommended treatment included amphotericin B deoxycholate (1 mg per kilogram per day) plus flucytosine (100 mg per kilogram per day) for 7 days, followed by fluconazole (1200 mg per day) for 7 days (control). Amphotericin B binds to ergosterol in the fungal cell membrane, which leads to the formation of pores, ion leakage and ultimately fungal cell death. Such benefits of Amphotericin B in Cryptococcal meningitis treatment drive the growth of the Cryptococcosis Market Share.
However, Fluconazole Drugs are estimated to grow with the fastest CAGR of 8.3% over the forecast period 2022-2027. This is due to the most effective Oral fluconazole 200 mg/d in maintenance therapy for AIDS-associated cryptococcal meningitis. Also, according to a research paper published in the American Society for Microbiology in December 2019, Fluconazole has a large safety usage database, is orally accessible and also has great central nervous system (CNS) penetration. Additionally, it has few clinically relevant drug-drug interactions. Hence fluconazole is a mainstay in the treatment of cryptococcal meningitis. Such effectiveness of fluconazole in Cryptococcus infections increases its demand and drives the growth of the Cryptococcosis Market share over the forecast period 2024-2030.
Cryptococcosis Market Segment Analysis - by End-user
The Cryptococcosis Market based on end-user can be further segmented into Hospitals, Ambulatory Surgical Centers, Specialised Clinics, Elderly Care Centers and others. The hospital segment held a dominant market share in 2021. This is due to the growing admission regarding HIV-related infections in recent years. According to the 2021-2022 annual report published by the Ministry of Health and Family Welfare Government of India, the new cases of HIV-related infection were 31,944 (20,467-52,007) in 2020. Such growing cases of HIV-related infections and the need for hospitalization drive the growth of the Cryptococcosis Market Share.
However, Elderly Care Centers are estimated to grow with the fastest CAGR of 9.1% over the forecast period 2022-2027. The growing geriatric population and their low immunity increase the chances of cryptococcosis infection in elderly people. Also, aging is associated with an increased risk of autoimmune diseases. According to the National Institute of Environmental Health Sciences, there are 23.5 million autoimmune disorders in the United States. Such a growing risk of autoimmune diseases in the elderly population makes them more susceptible to cryptococcus infection and increased demand for elderly care centers fuels the growth of the Cryptococcosis Market Share over the forecast period 2024-2030.
Cryptococcosis Market Segment Analysis - by Geography
North America held a dominant market share of 36% in 2021. The primary factors driving the Cryptococcosis market in North America are greater availability of antifungal medications like flucytosine, reimbursement for disease screening and availability of advanced diagnostics techniques for the detection of cryptococcus with biomarker tests. Also, the growing cases of autoimmune diseases and the use of immunosuppressants increase the risk of cryptococcosis infection. According to the National Multiple Sclerosis Society, nearly one million people are living with MS in the United States in 2022. Such growing prevalence of various autoimmune diseases in the United States further drives the growth of the Cryptococcosis Market Size.
Furthermore, the Rest of the World is estimated to grow with the fastest CAGR over the forecast period 2024-2030. This is owing to the increasing prevalence of HIV-related cryptococcosis infections in the Middle East and Africa, especially in Sub-Saharan countries where the prevalence of infections from cryptococcosis linked to HIV is relatively high. According to a research article published in National Center for Biotechnology Information (NCBI) in January 2020, annually, 278,000 people had cryptococcal antigenemia, with 73% of meningitis cases occurring in Sub-Saharan Africa. This is because of the growing cases of HIV and AIDS in this region. As per the Joint United Nations Program on HIV/AIDS (UNAIDS) report 2022, Eastern and Southern Africa is most heavily affected by HIV, with 20.6 million (18.9 million–23.0 million) people - 54% of all people living with HIV in the world. Western and Central Africa had 5 million (4.5 million–5.6 million) people living with HIV at the end of 2021. Such a high prevalence of HIV & AIDS increases the risk of Cryptococcosis in this region and fuels the growth of the Cryptococcosis Market size over the forecast period 2024-2030.
Cryptococcosis Market Drivers
Growing Prevalence of HIV & AIDS Drive Market Growth:
People with low immunity are more prone to Cryptococcosis infections. According to the Centers for Disease Control and Prevention (CDC), cryptococcosis infections are common in people with a weak immunity (especially those having advanced HIV/AIDS) and in people taking corticosteroids or other medications that weaken immunity. People with HIV & AIDS are very susceptible to all types of infections including cryptococcosis infections. According to the World Health Organisation (WHO), HIV is a major global public health concern and takes claimed 40.1 million (33.6–48.6 million) lives. In 2021, about 38.4 million (33.9–43.8 million) people were living with HIV. Also, 650,000 (510,000-860,000) people died from HIV-related causes and 1.5 million (1.1–2.0 million) people acquired HIV. Such a growing prevalence of HIV&AIDS and the high risk of Cryptococcosis infection in this population fuel the growth of the Cryptococcosis Industry over the forecast period 2024-2030.
High Cases of Organ Transfer Drive Cryptococcosis Market Growth:
After the organ transplant treatment, the need for immunosuppressant drugs is required to prevent the immune system from attacking or rejecting the donor organ. The immunosuppressant drugs lower the immunity. The growing cases of organ transplants increase the demand for immunosuppressant drugs in the market. In 2021, 41,354 organ transplants were performed in the United States. In 2021, the United States witnessed 24,669 kidney transplants, 9,236 liver transplants and 3,817 heart transplants. Such a growing case of organ transplants and the use of immunosuppressants weaken the immunity of the patients. With low immunity in people with organ transplant, there is a high chance of infection from Cryptococcosis which drive the growth of the Cryptococcosis Industry over the forecast period 2024-2030.
Cryptococcosis Market Challenge:
High Cost of Treatment is Hampering Market Growth
The per-patient cost of Cryptococcal meningitis treatment in low and middle-income countries (LMICs) is very high. According to the research paper published in the National Center for Biotechnology Information in June 2020, the cost and availability of induction therapy for cryptococcal meningitis (CM) are both quickly evolving. The cost for Flucytosine (500 mg pills) per 100 pack is $75 in LMICs with a high HIV burden. In Uganda, amphotericin B and fluconazole drugs cost $400 for 2 weeks. Consolidation and maintenance therapy with fluconazole drugs for 1 year cost $60 per meningitis survivor ($0.15 per 200 mg fluconazole drugs) in LMICs. Thus, with an annual estimated incidence of 12,200 meningitis cases in Uganda, $5.6 million would be required for initial meningitis diagnosis and meningitis treatment. Such a high cost for Cryptococcosis increases the healthcare burden in low and middle-income countries and may limit the growth of the Cryptococcosis Industry over the forecast period 2024-2030.
Cryptococcosis Market Industry Outlook
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Cryptococcosis Market. The top 10 companies in the Cryptococcosis Market are:
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- Gilead Sciences, Inc.
- Janssen Pharmaceuticals, Inc.
- Abbott Laboratories
- Novartis AG
- Pfizer Inc.
- Valeant Pharmaceuticals Inc.
- Glenmark Pharmaceuticals
- Sigmapharm Laboratories LLC.
- Lupin Ltd
- Amplyx Pharmaceuticals
Recent Developments
- In June 2022, Glenmark Pharmaceuticals Ltd announced the acquisition of the approved generic versions of certain over-the-counter drugs from Wockhardt Ltd in the United States. The acquisition by the company's fully-owned subsidiary Glenmark Pharmaceuticals Inc, USA includes the approved abbreviated new drug applications (ANDAs) for famotidine tablets, 10 mg and 20 mg used to treat and prevent ulcers in the stomach and intestine.
- In April 2022, Lupin Ltd completed the acquisition of a portfolio of brands from Anglo-French Drugs & Industries Limited (AFDIL) and its associates. The acquisition of the AFDIL brands takes the company further into shaping its portfolio to emerge as a leading pharmaceutical company in India.
- In February 2022, Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced a strategic collaboration with Remix Therapeutics. This collaboration aims to work on the discovery and development of small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform.
Relevant Titles
Report Code: HCR 0022
Report Code: HCR 64783
Report Code: HCR 16877
For more Lifesciences and Healthcare Market reports, please click here